Roche Holdings Ltd ADR (RHHBY)

$40.32 -0.12 (-0.30%)
Market Cap 257.92B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 13.79
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 1,150,200
Avg Vol 1,680,496
Day's Range N/A - N/A
Shares Out 6.38B
Stochastic %K 53%
Beta 0.45
Analysts Sell
Price Target $44.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
monterocky848
monterocky848 Jul. 7 at 6:31 PM
$CGON $CLDI $MRK $REGN $RHHBY who fucking cares
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 7 at 1:07 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs $CLDI $REGN $CGON $RHHBY $MRK https://ibn.fm/fSEy9
0 · Reply
funnymoney90210
funnymoney90210 Jul. 3 at 3:01 PM
$NRSN Which Drug companies have offices in LA, San Fran, and NYC you ask? Let's see $PFE $JNJ $BMY and $RHHBY Which one is making a deal next week?
4 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 2 at 11:41 AM
$TNXP this is major news given the size of the PD-1 market. Combine this with Tonmya’s blockbuster potential in fibromyalgia and the main PD1 companies may be interested in a BO ( $BMY , $MRK , $RHHBY , BeOne (formerly Beigene) 👍 GLB 👍 ☘️ 🐂
0 · Reply
Quantumup
Quantumup Jul. 1 at 12:10 PM
Cantor🏁 $TRVI Overweight-$25 and said, "We are initiating coverage of $TRVI with an OW rating and $25 PT, representing ~300% upside from current levels." $PLRX $RHHBY Cantor added, "This is about as high conviction a call as we'll ever have for a pre-commercial program." Cantor went on to say:
1 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Jul. 1 at 12:00 AM
$NUVL $NUVB $PFE $BMY $RHHBY Here's a question, why aren't they saying this about Nuvation's drug, it's already been approved? This is what I have been saying all along, Nuvalents drug is superior to Nuvation's drug.
2 · Reply
Shagg85
Shagg85 Jun. 30 at 8:49 PM
$BMY $NUVB $NUVL $PFE $RHHBY pump on your Own ticker. they aren’t even close to release or FDA approval
0 · Reply
Quantumup
Quantumup Jun. 30 at 8:39 PM
Goldman Sachs assigned $NUVL at a Buy-$105 after its previous No Rating on their Initiation, plus⬆️its peak sales ests for nela/zide to ~$7B WW non-risk-adj'd, or ~$5B risk-adj'd in 2040. $NUVB $PFE $BMY $RHHBY Goldman Sachs said in its note:
0 · Reply
Quantumup
Quantumup Jun. 30 at 5:56 PM
TD Cowen reiterated $AUPH Buy-$11 and said, "Phase I healthy volunteer SAD data for aritinercept/AUR200 (BAFF/April inhibitor) appear to be matching other competitive/BIC programs in development." $VRTX $OTSKY LLY REGN AMGN GILD $GSK $RHHBY TD Cowen went on to say:
1 · Reply
Quantumup
Quantumup Jun. 30 at 5:34 PM
Leerink reiterated $AUPH Outperform-$10 $VRTX $OTSKY $GSK $RHHBY GILD BMY Leerink said said in its note to investors:
0 · Reply
Latest News on RHHBY
No data available.
monterocky848
monterocky848 Jul. 7 at 6:31 PM
$CGON $CLDI $MRK $REGN $RHHBY who fucking cares
0 · Reply
NetworkNewsWire
NetworkNewsWire Jul. 7 at 1:07 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs $CLDI $REGN $CGON $RHHBY $MRK https://ibn.fm/fSEy9
0 · Reply
funnymoney90210
funnymoney90210 Jul. 3 at 3:01 PM
$NRSN Which Drug companies have offices in LA, San Fran, and NYC you ask? Let's see $PFE $JNJ $BMY and $RHHBY Which one is making a deal next week?
4 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 2 at 11:41 AM
$TNXP this is major news given the size of the PD-1 market. Combine this with Tonmya’s blockbuster potential in fibromyalgia and the main PD1 companies may be interested in a BO ( $BMY , $MRK , $RHHBY , BeOne (formerly Beigene) 👍 GLB 👍 ☘️ 🐂
0 · Reply
Quantumup
Quantumup Jul. 1 at 12:10 PM
Cantor🏁 $TRVI Overweight-$25 and said, "We are initiating coverage of $TRVI with an OW rating and $25 PT, representing ~300% upside from current levels." $PLRX $RHHBY Cantor added, "This is about as high conviction a call as we'll ever have for a pre-commercial program." Cantor went on to say:
1 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Jul. 1 at 12:00 AM
$NUVL $NUVB $PFE $BMY $RHHBY Here's a question, why aren't they saying this about Nuvation's drug, it's already been approved? This is what I have been saying all along, Nuvalents drug is superior to Nuvation's drug.
2 · Reply
Shagg85
Shagg85 Jun. 30 at 8:49 PM
$BMY $NUVB $NUVL $PFE $RHHBY pump on your Own ticker. they aren’t even close to release or FDA approval
0 · Reply
Quantumup
Quantumup Jun. 30 at 8:39 PM
Goldman Sachs assigned $NUVL at a Buy-$105 after its previous No Rating on their Initiation, plus⬆️its peak sales ests for nela/zide to ~$7B WW non-risk-adj'd, or ~$5B risk-adj'd in 2040. $NUVB $PFE $BMY $RHHBY Goldman Sachs said in its note:
0 · Reply
Quantumup
Quantumup Jun. 30 at 5:56 PM
TD Cowen reiterated $AUPH Buy-$11 and said, "Phase I healthy volunteer SAD data for aritinercept/AUR200 (BAFF/April inhibitor) appear to be matching other competitive/BIC programs in development." $VRTX $OTSKY LLY REGN AMGN GILD $GSK $RHHBY TD Cowen went on to say:
1 · Reply
Quantumup
Quantumup Jun. 30 at 5:34 PM
Leerink reiterated $AUPH Outperform-$10 $VRTX $OTSKY $GSK $RHHBY GILD BMY Leerink said said in its note to investors:
0 · Reply
biolover
biolover Jun. 27 at 6:08 PM
$VKTX $LLY tell that idiot tirzepatide ( projected $40 B annualized by year end ) minor mod of its predecessor . I blocked this clown. You guys wasting your time on these guys. $NVO missteps can go in history books. First acquired RG7697, and called it NNC0090-2746; a dual GIP/GLP-1 agonist that was initially developed by Marcadia Biotech before moving to Roche and then Novo. Lilly copies tirzapetide with minor modification from this molecule ( plus fatty acid size and location different .. clinical experience shows the importance of that ) After dumping that original molecule novo rushed its newer GLP1-GIP dual agonist ( NN 130 ) that they recently dumped due to toxicity. $RHHBY also dumped the first GLP1-GIP peptide ( and then bought Carmot drug which seems to be failure ) and gave first oral GLp1 small molecule to Lilly for $50 m( now known as orfoglipron)
2 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Jun. 27 at 3:30 PM
$LMDX $RHHBY
0 · Reply
investvibes
investvibes Jun. 26 at 11:26 PM
$LMDX $RHHBY 1:1 conversion?
4 · Reply
BioRich
BioRich Jun. 26 at 2:37 AM
@AZ89 Thanks for the question about $SRPT and their relationship with $RHHBY. As mentioned, I think that relationship is likely very strained. I'm not sure Buyout is on the table given their current relationship but do have a better idea for Sarepta's future. I think $SRPT Buys, or at least lucratively partners with, $CAPR. I think it's a win for both, although non-business-related many probably think that they aren't a good marriage. Financially and business-wise, it makes sense. One up and comer with a bright future ($CAPR) pairing with a damaged class leader ($SRPT). Depending on how they play it, they will be able to calm the storm around SRPT and give solid foundational support for CAPR as they navigate the FDA and commercial launch hurdles. Doug and Linda could become a Co-CEO power couple. What do you think about that idea? Follow/Subscribe for more thoughts and perspective. Let's make some money. Cheers!
5 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 26 at 2:36 AM
$LMDX $NDAQ $RHHBY #Gatesfoundation Despite investing in the development and commercialization of this platform—particularly the TB test which is likely to reshape diagnostics in low-resource settings—public shareholders received no compensation. There was no vote, no fairness opinion, and no transparency regarding future revenue participation from the assets we funded. We are now formally asking: 1. When and how does Roche intend to compensate LMDX shareholders for assets—especially the TB test IP and future revenues—acquired under this transaction? 2. Who at Roche is responsible for disclosures and negotiations involving this technology, and are royalty agreements or equity transitions in place involving former LMDX insiders? 3. Will Roche provide an itemized breakdown of the $295M valuation, specifically how the TB pipeline and SureSensors technology were valued in the sale? We are prepared to escalate our concerns
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Jun. 26 at 2:33 AM
$RHHBY $LMDX #BillGates $NDAQ Dear Roche Investor Relations, I am writing to request formal clarification regarding Roche’s acquisition of LumiraDx’s assets, particularly those related to its transformational TB test, developed in partnership with the Gates Foundation. Shareholders were informed that the transaction with Roche was a limited asset sale of point-of-care (POC) technology under administration. However, based on publicly available filings, statements by Roche, and patent records, it is now evident the transaction included much more: • The entire IP portfolio, including patents granted post-sale; • Active pipeline development, including the TB test project with global public health implications; • Ongoing operational continuity, partnerships, and integration into Roche’s decentralized diagnostics strategy.
0 · Reply
Quantumup
Quantumup Jun. 24 at 5:18 PM
Leerink⬆️the PT on $NUVL to $140 from $125 and reiterated at an Outperform. $NUVB $PFE TPTX - $BMY $RHHBY Leerink said in its note to investors:
0 · Reply
Quantumup
Quantumup Jun. 24 at 1:16 PM
Guggenheim⬆️ $CDTX to $68 from $50, reiterated, Buy and said, "The NAVIGATE Phase 2b data reflect striking efficacy and a clean safety provide, with 76.1% protective efficacy (PE) at the 450mg dose exceeding our expectations." $JNJ $RHHBY $GILD $SNY GSK NVS AZN Guggenheim added, "Importantly, data across temperature thresholds showed dose-response in the primary endpoint (38.0C), as well as CDC and prior flu preventative (37.8C and 37.2C), and the 450mg dose cohort consistently demonstrated >70% PE and highly stat sig results (p<0.0001) at each fever threshold. Each dose demonstrated a clean safety profile, with ISRs similar between treated and pbo participants and no treatment-related SAEs. Guggenheim went on to say:
0 · Reply
Quantumup
Quantumup Jun. 24 at 1:03 PM
H.C. Wainwright⬆️the PT on $CDTX to $53 from $41, reiterated Buy and said, "Cidara announced positive topline results from its Phase 2b trial, NAVIGATE, on June 23, evaluating CD388, the company's lead influenza drug-Fc conjugate (DFC) candidate." $JNJ $RHHBY $GILD $SNY GSK NVS AZN H.C. Wainwright added, "While we describe the findings in more detail below, we note that the trial met its primary endpoint of preventive efficacy (PE), which demonstrates the percentage by which a prevention method reduces the chance of getting sick compared to not using the intervention, as well as all secondary efficacy endpoints across all doses. H.C. Wainwright went on to say:
0 · Reply
AnJaMi
AnJaMi Jun. 23 at 6:57 PM
$LMDX $RHHBY we all claim it!!!
0 · Reply
M3l1MCK
M3l1MCK Jun. 23 at 6:53 PM
$LMDX $RHHBY I CLAIM IT!!!!!
2 · Reply
green_going_up
green_going_up Jun. 23 at 4:54 PM
$LCTX We need $RHHBY to ACCELERATE the Phase 2B - No Reason why Roche / Genentech shouldn't be able to fill the trial ASAP with this data and the large GA Population.
0 · Reply